Diabetico has uncovered a primary metabolic dysfunction present in T1D as well as identifying a new and unique protein that has the potential to be the target of new precision medicine for early diagnosis and effective treatment of T1D.

We're developing a proprietary point of care diagnostic test to identify T1D with precision, with the potential to screen a broader population for TD1. Our preliminary studies have demonstrated >90% accuracy in identifying T1D in animal models and patients. We have identified a path to develop a companion-targeted therapy, potentially stopping progression T1D.